ZEALAND PHARMA A/S: Financial statements 2021
CVR: 20045078
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
ZEALAND PHARMA A/S (CVR 20045078) has filed annual accounts for 2021. In 2021, the company reported revenue of DKK 292,567,000 and a net result of DKK -1,018,149,000 compared with DKK -846,729,000 the year before. That is a decrease of 17.2% compared with the year before. The profit margin was -348%. Equity in the 2021 report amounted to DKK 927,803,000. The solvency ratio was 44.9%. The company had 346 employees in the financial year.
- Revenue
- DKK 292,567,000
- Gross Profit
- DKK 173,753,000
- Profit/Loss
- DKK -1,018,149,000
- Equity
- DKK 927,803,000
- Total Assets
- DKK 2,067,629,000
- Employees
- 346
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | 292.6M | 173.8M | -1B | 927.8M | 346 |
| 2020 | 353.3M | 262.7M | -846.7M | 1.2B | 297 |
| 2019 | 41.3M | - | -571.5M | 1.2B | - |
| 2018 | 38M | - | 581.3M | 1.1B | - |
| 2017 | 139.8M | - | -272.3M | 528.5M | - |
Official annual report
Find more companies like ZEALAND PHARMA A/S
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2021
ZEALAND PHARMA A/S has published its interim report for the period January 1, 2021 to September 30, 2021.
ZEALAND PHARMA A/S has published its interim report for the period January 1, 2021 to June 30, 2021.
As of September 1, 2021, Anneline Nansen has joined the board of directors of ZEALAND PHARMA A/S.
As of September 1, 2021, Gertrud Koefoed Rasmussen has left the board of directors of ZEALAND PHARMA A/S.
As of August 31, 2021, Anneline Nansen has left the board of directors of ZEALAND PHARMA A/S.
ZEALAND PHARMA A/S has published its annual report for 2020. Revenue came to DKK 353,314,000, and the net result was DKK -846,729,000.
About ZEALAND PHARMA A/S
ZEALAND PHARMA A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 1997. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named ZEALAND PHARMACEUTICALS A/S and PEPTIDE PROBE TECHNOLOGIES ApS. The management consists of Adam Sinding Steensberg and Henriette Wennicke. The board consists of Alf Gunnar Martin Nicklasson (chair), Kirsten Aarup Drejer, Adam Krisko Nygaard and Anneline Nansen. The company's owners include ZEALAND PHARMA A/S, Van Herk Investments B.V. and Van Herk Management Services B.V.. The company has 575 employees (2026). In 2025, the company reported revenue of DKK 9,214,860,000 and a net result of DKK 6,455,008,000 compared with DKK -1,078,828,000 the year before. Equity in the 2025 report amounted to DKK 14,830,613,000.
